Technology

Steve Gens and Remco Munnik offer five best-practice tips for achieving a definitive, trusted regulatory and product information asset base capable of supporting intelligent innovation.

In safety & pharmacovigilance, the requirement to capture, sift and process real-world adverse event data is vast and growing all the time. Why then, writes John Price, is the discipline lagging in its application of smart technology?

Thriving in the new COVID-19 world requires five key ingredients, which can be leveraged with a transformative approach to digital adoption in the pharma space.

Grünenthal's Florent Edouard and Veeva's Jan van den Burg talks about how the COVID-19 pandemic is changing the way the industry reaches and engages with its customers.

Developing a digital health solution that patients and HCPs will use requires creating technology that addresses unmet needs, integrates with clinical care pathways, and has strong user safeguards, writes Matt Norton.

Strategies for those chief information officers taking the digital reins at their organizations.

Dr. Jeanne Ross of the MIT Center for Information Systems Research discusses how to lead an organization’s digital transformation for the pursuit of new revenue models.

Archaic ways of working need to make way for more agile and nimble response mechanisms enabled by a systematic enterprise-wide digital upskilling strategy, writes Anand Kiran.

Anita Moser, Michael Davis, Dharmendra Sahay outline UCB's measured approach to scaling its AI capabilities.

Exploring the challenge for pharma in adapting multichannel marketing strategies for the global stage, while trying to refine messages and communicate a brand identity to multiple local audiences.

Amid concerns over a potential 'wild west' climate for data analytics in pharma, taking a long-term, proactive, and enterprise view of your company’s data may be the best way to keep your organization and reputation safe.

How to capitalize on the rise of omnichannel engagement in pharma and pursue myriad modes of message delivery in today’s digital world.

A look at the ongoing barriers and opportunities in building connections between HCPs, patients, and pharma through social media.

The key to success in a hypercompetitive marketplace is to create targeting plans that get ahead of tomorrow’s prescriptions, write Janardhan Vellore and Daniel Wetherill.

In 2020, AI will become pervasive in enterprise applications and embedded within specific commercial workflows, writes Paul Shawah.

Having invested heavily in new regulatory database systems, life sciences firms owe it to themselves to capitalize on the insights locked within those rich data assets, writes David Gwyn.

How successful commercial teams will balance the continued shift toward personalized medicine and the increased concentration on data privacy.

Goals for IDMP in Europe must not be diluted in 2020, if standardized medicinal product data is to be of tangible real-world benefit, says Remco Munnik.

Kellie Rademacher identifies some of the key questions to consider when choosing an AI partner.

Graham Francis sets out 5 critical business drivers for building a global enterprise labelling strategy over the year ahead.

How machine learning can provide an on-demand portfolio-wide view of optimal provider targeting and related field deployment.

Organizations need to be correctly set up to deploy AI and machine learning. A new approach to processes and content is often required, write Jan van den Burg and Abid Rahman.

Aiforia Technologies CEO Kaisa Helminen talks about the benefits of pharma embracing digital technologies, especially AI-assisted image analysis in the field of histopathology.

Technology grabbing the attention of watchful industry

Amid new findings on today’s C-suite mood and approach to digital transformation, experts-in a panel discussion and wider examinations by Pharm Exec editors-explore the intersection of data and technology and the areas that must evolve to meet the digital health demands of tomorrow.